In CEO News:

Nuon Therapeutics Inc., of San Mateo, Calif., has named Lee M. Rauch president and CEO. Rauch previously was acting head of corporate development for Onyx Pharmaceuticals and served as chief business officer at Point Biomedical and at Onyx. She also was senior vice president of corporate development at COR Therapeutics.

Ohr Pharmaceutical Inc., of New York, has named Irach B. Taraporewala CEO. He formerly was vice president of regulatory affairs and clinical research at Mystic Pharmaceuticals Inc. and served as senior consultant at Parexel International Corp. The company also named Sam Backenroth interim chief financial officer and vice president of business development.

In other A&A news:

Aastrom Biosciences Inc., of Ann Arbor, Mich., appointed Daniel R. Salomon, Karen K. Hirschi, Marc Penn, and Mahendra Rao to its newly formed scientific advisory board.

Ampio Pharmaceuticals Inc., of Greenwood Village, Colo., appointed Philip H. Coelho to its board.

Ardea Biosciences Inc., of San Diego, appointed Stephen R. Davis executive vice president and chief operating officer.

CeQur SA, of Montreux, Switzerland, appointed Robert O'Holla executive vice president for regulatory affairs.

Curemark, of Rye N.Y., named Matthew F. Heil senior vice president of research and development.

Dendreon Corp., of Seattle, named Varun Nanda senior vice president of global commercial operations.

Entest BioMedical Inc., of San Diego, hired Tammy Reynolds as chief financial officer.

Forma Therapeutics, of Cambridge, Mass., appointed Robert Forrester chief operating officer.

Idera Pharmaceuticals Inc., of Cambridge, Mass., appointed Robert Arbeit vice president of clinical development and Nicola La Monica vice president of biology, and promoted Timothy Sullivan to vice president of development programs and alliance management.

Ikaria Holdings Inc., of Clinton, N.J., elected Howard H. Pien to its board.

International Stem Cell Corp., of Oceanside, Calif., named Hans-Dieter Volk and Matthias von Herrath to its scientific advisory board.

K-V Pharmaceutical Co., of St. Louis, appointed Stephen A. Stamp chief financial officer and treasurer.

Neogenix Oncology, of Great Neck, N.Y., elected Lynn Krominga to its board.

Patheon Inc., of Toronto, named Mark Kontny president of global pharmaceutical development services and chief scientific officer.

QLT Inc., of Vancouver, British Columbia, named Dipak Panigrahi senior vice president of research and development and chief medical officer.

Roche AG, of Basel, Switzerland, named Luca Santarelli head of the central nervous system discovery and translational area.

Silence Therapeutics plc, of London, appointed Max Herrmann chief financial officer and company secretary.

Somaxon Pharmaceuticals Inc., of San Diego, appointed Tran B. Nguyen vice president and chief financial officer.

Stellar Pharmaceuticals Inc., of London, Ontario, appointed Steven H. Goldman to its board.

Versartis Inc., of Mountain View, Calif., named Paul Westberg senior vice president of business development.